Overview

Ampligen in Chronic Fatigue Syndrome

Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open label study of Ampligen in patients with chronic fatigue syndrome.
Details
Lead Sponsor:
AIM ImmunoTech Inc.
Hemispherx Biopharma
Treatments:
Poly I-C
poly(I).poly(c12,U)